← Human Trials & Peer-Reviewed Studies
A Study of HRS-4729 Injection in Participants With Type 2 Diabetes
Plain-language guide to NCT07843862: phase 2 randomized trial of Mazdutide, 240 participants. Who took part, design and what was measured.
Key Facts
- Registry ID
- NCT07843862
- Phase
- phase 2
- Status
- not yet recruiting
- Start
- 2026-10
- Completion (planned or actual)
- 2027-04
- Participants
- 240 (estimated)
- Design
- randomized, quadruple-blind, treatment
- Conditions studied
- Type 2 Diabetes
- Results posted
- not yet
What This Study Did, in Plain Language
What Was Tested
The trial (phase 2) is built around Mazdutide.
It had six arms (groups): Treatment group A (experimental), Treatment group B (experimental), Treatment group C (experimental), Treatment group D (experimental) and Mazdutide (active comparator).
The registry classes the interventions as drug.
Who Took Part
The registry lists 240 planned participants were the target.
It was open to people of any sex aged from 18 years up to 65 years.
Healthy volunteers were not accepted; participants needed the condition being studied.
Examples of who could join: Have Type 2 Diabetes.
The full record lists 3 inclusion and 8 exclusion criteria; among the exclusions: have uncontrolled hypertension; have type 1 diabetes, or specific types of diabetes; history of acute diabetic complications or severe hypoglycemic events.
How the Study Was Run
The set-up was randomized, parallel-group and quadruple-blind.
The participants were allocated by chance, so the Mazdutide group and the comparison group should start out alike.
The Mazdutide group and the comparison group ran side by side rather than switching.
Neither the participants nor the staff measuring them knew who was on Mazdutide, so expectations could not easily colour the readings.
Those kept unaware of assignments: participant, care provider, investigator and outcomes assessor.
It started in 2026-10 with completion listed for 2027-04.
It ran at 2 sites in China (2).
Its stated primary purpose is treatment.
What Was Measured
Researchers chose this as the main measure: Change From Baseline in HbA1c (time frame: Baseline, Week 28).
It also tracked 4 secondary outcomes, for example Percent Change From Baseline in Body Weight, Change From Baseline in Fasting Plasma Glucose and TEAEs.
What This Means in Plain Language
Put simply, this is a phase 2, randomized trial of Mazdutide in 240 people.
Its status is not yet recruiting; no results are posted to the registry yet, so nothing here describes outcomes.
More context: the Mazdutide compound page, all human trials.
Our Notes on the Compound
Mazdutide: A dual GLP-1 and glucagon receptor agonist with approvals announced in China for weight management and type 2 diabetes.
Related Pages
Source: ClinicalTrials.gov record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.